Tag Archives: MACI for osteoarthritis

Arthritis Biosimilar

FDA OKs First in a New Generation of Knee Cartilage Repair

The Food and Drug Administration (FDA) recently approved a new product to repair damaged knee cartilage using cells from the patient’s own knee. The product, called Matrix Associated Chondrocyte Implantation (MACI), is approved for use in people younger than age 55 who have what are known as “focal chondral defects,” which can be a precursor to knee osteoarthritis (OA). Experts say, while MACI is not for use in people with knee OA, it does provide a new treatment option to prevent OA from developing in a particular group of patients.
Continue reading FDA OKs First in a New Generation of Knee Cartilage Repair